Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs SAP SE (SAP) Price & Performance

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs SAP SE — how do they compare? Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B), while SAP SE trades at $203.99 (market cap $240.81B). The key difference: SAP SE is far larger — about 14.6× Neurocrine Biosciences Inc's market cap, and SAP SE pays a 1.4% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

NBIXSAP
Market Cap
$16.46B$240.81B
Sector
HealthTechnology
52-Week High
$185.50$280.46
52-Week Low
$123.10$146.38
Enterprise Value
$16.48B$239.52B
Dividend Yield
1.4%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About SAP SE

Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.

Read more on SAP